Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
- Real-World Phase-Appropriate Control Lessons For mAb/ADC Manufacturers
- High Specific Productivity For Leaner Sustainable Bioprocessing
- New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
- Taking The First Steps Towards Digitalizing Biopharma Development
- Facility Considerations When Retrofitting Legacy Sites For ADCs
- In Vivo's Biggest Threat — Comparison To Old Models
- Managing Supply Chain Risk In Scale-Up And Multisite Trials
EDITOR'S DESK
-
FDA Releases Draft Guidance To Accelerate Biosimilar Development
New FDA draft guidance aims to reduce the timeline and cost of developing biosimilars.
Experts discuss innovation in antibody-drug conjugate (ADC) technology and how these impact CMC strategy. This summary captures key takeaways from the Bioprocess Online Live event "Evolving CMC Strategies To Enable Next-Gen ADCs."
Capacity isn’t the choke point—capability is; this piece ranks nine fast-growing outsourcing segments and shows sponsors how to win by locking in modality-proven partners early.
At BioProcess International 2025, leaders from AbbVie and Amgen gave keynote presentations about how their companies are advancing product development through digital tools.
AI consultant Kat Kozyrytska advocates for ethical AI adoption and explains its potential to foster collaboration across the industry.
GUEST COLUMNISTS
-
Real-World Phase-Appropriate Control Lessons For mAb/ADC Manufacturers
Effective mAb and ADC manufacturing control strategies evolve through the phases. These four principles should guide your strategy design as goals shift.
-
High Specific Productivity For Leaner Sustainable Bioprocessing
Improving specific productivity moves the goal beyond pumping out higher titers, but it demands a deeper understanding of cellular biology and protein expression.
-
New ISPE Framework Targets Uncertainty In Pharma's AI Deployment
International Society for Pharmaceutical Engineering members developed the guide to offer a risk-based framework for evaluating, implementing, and maintaining AI systems.
-
Facility Considerations When Retrofitting Legacy Sites For ADCs
Antibody-drug conjugate manufacturing requires, among other things, unidirectional flow and air locks for people and materials. Facilities often lack these attributes.
-
In Vivo's Biggest Threat — Comparison To Old Models
In vivo CAR-T is not simply ex vivo without a manufacturing step. It is a different modality that relies on biological systems to regulate outcomes.
-
Managing Supply Chain Risk In Scale-Up And Multisite Trials
Scaling trials across sites can lock in supply risk early. Learn how biologic variability, long lead times, and multisite complexity threaten trials and how to spot warning signs fast.
-
The 5-Layer Fix For AI Failure In Pharmaceutical Manufacturing
The promise of AI is colliding with the harsh reality of data chaos in pharma manufacturing. This article explores why most AI investments fail, and a 5-layer solution.
-
Why Use Total Organic Carbon Analysis For Cleaning Validation?
Total organic carbon analysis is probably the most “fit for use” analytical method to validate cleaning processes, particularly within a science- and risk-based approach.
BIOPROCESSING WHITE PAPERS
-
Beyond Glycan Control: The IVGE Advantage In Key Biopharma Applications
In Vitro Glycoengineering (IVGE) precisely controls glycosylation to optimize biopharma workflows, serving as a critical platform for advancing key therapeutic areas in today's industry.
-
Selecting A CDMO For Custom Activated PEGs1/27/2026
Custom-activated PEGs require thoughtful planning and precise analytical control. Discover key considerations for selecting a partner capable of supporting scalable, compliant PEGylation.
-
Tablet Manufacturing Technologies For Solid Drug Formulation4/2/2025
Compressed tablets are common oral solid dosages that contain the API and various excipients. Learn about the critical steps in selecting manufacturing methods and excipients to achieve the desired therapeutic effects and stability.
-
The Impact Of Artificial Intelligence On CQV7/23/2025
AI is revolutionizing CQV in life sciences by automating documentation, enabling real-time monitoring, and driving predictive quality to boost efficiency and compliance across validation processes.
-
Application Of Plant And Process Models1/22/2025
Explore innovative process and facility models that optimize efficiency, sustainability, and cost-effectiveness in biopharmaceutical manufacturing.
-
Generation Of Stable CHO Cell Lines For Protein Production3/22/2024
By following the five steps of a specialized protocol, exceptional yields and stable cell lines can be achieved in CHO cells using antibiotic selection.
BIOPROCESSING APP NOTES & CASE STUDIES
- Forget About Isolators: Switching From Manual Vial To Automated Bag Filling
- A Paradigm Shift From Glass Benchtop Bioreactors
- Bioconversion Of Babassu Mesocarp Flour Into Single-Cell Protein In A Controlled Bioreactor System
- Simplified LV And AAV Clarification With TFDF-Based Intensified Virus Production
- How A CDMO Gained 40%+ Efficiency By Generating Automated APQRs
- Taking The First Steps Towards Digitalizing Biopharma Development
- Bioprocess Online's 2025 Editorial Reflections
- FDA Releases Draft Guidance To Accelerate Biosimilar Development
- Supporting The Next Generation Of ADCs
- AbbVie And Amgen's Blueprint To Digitalize Biomanufacturing
- On The Ground At BPI: Kat Kozyrytska On Ethical AI And Collaboration
- On The Ground At BPI: Takeda's Amy Shaw On Scaling Cell Therapy Manufacturing
BIOPROCESS ONLINE CONTENT COLLECTIONS
This collection of articles digs into the industry’s growing focus on knowledge management as an indispensable facet of biomanufacturing and pharmaceutical development, exploring how it plays into risk management, quality, vendor relationships, and supply chain resilience.
More Content CollectionsFEATURED PRODUCTS AND SERVICES
ON-DEMAND WEBINARS
- Selecting A Prefillable Syringe System With Confidence
- Designing Drug Substance Processes For Fill-Finish Compatibility
- Accelerating Antibody Screening With A Scalable Protein Expression Platform
- Viral Clearance Strategies For Monoclonal Antibodies And Proteins
- Regulatory Compliance And Advanced Solutions For Aseptic Environmental Monitoring
INDUSTRY NEWS
NEWSLETTER ARCHIVE
- 02.12.26 -- Optimizing Cell Line Development With Emerging Technologies
- 02.12.26 -- Taking The First Steps Towards Digitalizing Biopharma Development
- 02.11.26 -- Sharpen Your Chromatography Performance
- 02.11.26 -- Do's And Don'ts Of Material Handling When Retrofitting For ADCs
- 02.10.26 -- Transform Your Bioprocessing Workflow With Scalable, Automated, And Single‑Use Technologies